Medicine Invention Design, Inc. (MIDI) - IORG0007849
Welcome,         Profile    Billing    Logout  
 6 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
XU, HAN
NCT01064466: Pharmacogenomics IND EXEMPT SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms

Active, not recruiting
2/3
600
US
ETOPOSIDE - Usual, Etoposide Injection Chemotherapy, ETOPOSIDE - Study, Etoposide Capsule Chemotherapy
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, UnitedHealthcare
Small Cell Lung Cancer
11/24
12/24
COV19-DS, NCT03348670: Pharmacogenomics IND EXEMPT SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms

Active, not recruiting
2/3
600
US
Abiraterone - Usual, ZYTIGA - abiraterone acetate tablet, film coated plus RAYOS - prednisone tablet, delayed release plus ORGOVYX - relugolix tablet, film coated for Oral, Abiraterone - Study, ZYTIGA - abiraterone acetate tablet plus RAYOS - prednisone tablet, delayed release plus ORGOVYX - relugolix tablet, film coated for Oral
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Prostate Cancer
05/24
05/24
Drugs-SNPs, NCT05987956: Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms

Not yet recruiting
2/3
600
US
Alectinib - Usual, Usual ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily, Alectinib - Study, Study ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Non-small Cell Lung Cancer
11/24
12/24
Drugs-SNPs, NCT06062810: Pharmacogenomics IND EXEMPT SNP Clinical Study - Crizotinib and Single Nucleotide Polymorphisms

Not yet recruiting
2/3
600
US
Crizotinib - Usual, Crizotinib Chemotherapy (high dose), Crizotinib - Study, Crizotinib Chemotherapy (low dose)
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Non-Small Cell Lung Cancer
12/24
12/24
NCT02403505: Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV

Active, not recruiting
1
20
US
9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use, 9vHPV Vaccine plus BCG Organism Mix
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
HPV Infection
02/24
02/24
COV19-APTP-B, NCT03305341: Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologics

Active, not recruiting
1
20
US
COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection, COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, PPD
Covid19
07/24
07/24

Download Options